A Study to Assess the Drug Levels of Repotrectinib in Healthy Participants and Participants With Moderate and Severe Hepatic Impairment
← catalyst calendarSponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
18actual
Sites
3
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-04-29 | actual | When the study began enrolling |
| Primary completion | 2025-09-16 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-09-16 | actual | The whole study's end, after follow-up |
| First posted | 2024-04-08 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-10-06 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Hepatic Impairment
- Healthy Volunteers
Intervention
- Drug: Repotrectinib — also filed as BMS-986472
Primary outcomes
what the primary-completion date above is the date OFMaximum observed plasma concentration (Cmax)
measured Days 1 to 11
Time of maximum observed plasma concentration (Tmax)
measured Days 1 to 11
Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration (AUC(0-T))
measured Days 1 to 11
Area under the plasma concentration-time curve from time zero extrapolated to infinite time (AUC(INF))
measured Days 1 to 11
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed